GSK (NYSE:GSK) Shares Acquired Rep. Lisa C. McClain

28 Nov 2025, 14:08 by Teresa Graham · The Cerbat Gem

Representative Lisa C. McClain (R-Michigan) recently bought shares of GSK PLC Sponsored ADR (NYSE:GSK). In a filing disclosed on November 21st, the Representative disclosed that they had bought between $1,001 and $15,000 in GSK stock on October 30th. The trade occurred in the Representative’s “CHARLES SCHWAB 401K > SCHWAB 893” account.

Representative Lisa C. McClain also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Alibaba Group (NYSE:BABA) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Coherent (NYSE:COHR) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Clorox (NYSE:CLX) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Northern Trust (NASDAQ:NTRS) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Honda Motor (NYSE:HMC) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Home BancShares (NYSE:HOMB) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Five Below (NASDAQ:FIVE) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Pure Storage (NYSE:PSTG) on 10/31/2025.
Sold $1,001 – $15,000 in shares of BHP Group (NYSE:BHP) on 10/31/2025.

GSK Trading Down 0.5%

GSK stock traded down $0.23 during midday trading on Friday, hitting $47.79. 2,851,523 shares of the company’s stock were exchanged, compared to its average volume of 5,159,200. GSK PLC Sponsored ADR has a one year low of $31.72 and a one year high of $48.69. The stock’s fifty day moving average price is $44.83 and its 200-day moving average price is $41.03. The company has a market cap of $97.04 billion, a PE ratio of 13.50, a price-to-earnings-growth ratio of 1.90 and a beta of 0.50. The company has a debt-to-equity ratio of 1.07, a quick ratio of 0.57 and a current ratio of 0.87.

GSK (NYSE:GSK – Get Free Report) last issued its quarterly earnings data on Wednesday, October 29th. The pharmaceutical company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.26 by $0.22. GSK had a return on equity of 51.07% and a net margin of 17.16%.The business had revenue of $11.35 billion during the quarter, compared to analyst estimates of $8.21 billion. During the same period in the previous year, the firm earned $0.50 EPS. GSK’s quarterly revenue was up 6.7% compared to the same quarter last year. GSK has set its FY 2025 guidance at 4.730-4.810 EPS. Research analysts predict that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current fiscal year.

GSK Cuts Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, January 8th. Investors of record on Friday, November 14th will be paid a dividend of $0.4171 per share. This represents a $1.67 annualized dividend and a yield of 3.5%. The ex-dividend date of this dividend is Friday, November 14th. GSK’s dividend payout ratio (DPR) is presently 46.05%.

Analyst Ratings Changes

A number of brokerages have recently commented on GSK. Bank of America raised shares of GSK from an “underperform” rating to a “neutral” rating in a research report on Tuesday. Cfra set a $53.00 price objective on GSK in a research report on Thursday, October 30th. Wall Street Zen upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday, September 5th. Weiss Ratings restated a “buy (b)” rating on shares of GSK in a report on Wednesday. Finally, Jefferies Financial Group restated a “buy” rating on shares of GSK in a research note on Monday, October 27th. Two investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $44.13.

Check Out Our Latest Analysis on GSK

Hedge Funds Weigh In On GSK

Several hedge funds have recently made changes to their positions in the stock. NewEdge Advisors LLC boosted its position in shares of GSK by 8.6% in the first quarter. NewEdge Advisors LLC now owns 90,663 shares of the pharmaceutical company’s stock valued at $3,512,000 after acquiring an additional 7,148 shares during the period. Miller Howard Investments Inc. NY grew its position in shares of GSK by 0.8% during the 2nd quarter. Miller Howard Investments Inc. NY now owns 1,659,814 shares of the pharmaceutical company’s stock valued at $63,737,000 after purchasing an additional 13,023 shares in the last quarter. Acadian Asset Management LLC raised its position in shares of GSK by 201.9% in the first quarter. Acadian Asset Management LLC now owns 3,982,324 shares of the pharmaceutical company’s stock worth $154,244,000 after buying an additional 2,663,270 shares in the last quarter. TD Private Client Wealth LLC raised its holdings in shares of GSK by 997.5% in the 2nd quarter. TD Private Client Wealth LLC now owns 78,019 shares of the pharmaceutical company’s stock valued at $2,996,000 after acquiring an additional 70,910 shares in the last quarter. Finally, Bard Financial Services Inc. grew its stake in GSK by 10.2% in the 2nd quarter. Bard Financial Services Inc. now owns 134,745 shares of the pharmaceutical company’s stock worth $5,174,000 after buying an additional 12,500 shares in the last quarter. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.

Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

GSK Company Profile

(Get Free Report)

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.